|Comparative Sensitivity of Urinary Cyfra 21-1, Urinary Bladder Cancer Antigen, Tissue Polypeptide Antigen and NMP22 to Detect Bladder Cancer|
|Marta Sanchez-Carbayo, Enrique Herrero, Julian Megias, et al.|
|Abramson Cancer Center of the University of Pennsylvania|
| Last Modified: November 1, 2001
Reviewers: Li Liu, MD
MethodA total of 111 patients with active bladder cancer, 76 patients with a history of bladder cancer and no evidence of active disease at the time of the study, and 80 symptomatic and asymptomatic controls comprised of healthy patients and patients with other urologic diseases and nonbladder malignancies were studied. All assays were performed an all patients, and compared for specificity and sensitivity.
DiscussionCytokeratin assays and nuclear matrix assay used in this study may be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of more than one tumor marker may improve sensitivity of the tests. More studies with larger sample size are needed to assess the diagnostic role of these markers.